Keryx Biopharmaceuticals Inc. (KERX) announced Monday morning that a supply interruption of Auryxia will occur, due to due to a production-related issue converting active pharmaceutical ingredient to finished drug product. As a result, the company has withdrawn its financial guidance for 2016.
from RTT - Before the Bell http://ift.tt/2aMdPko
via IFTTT
No comments:
Post a Comment